OS Therapies Inc’s prospectus supplement covers up to 5,874,094 common shares for resale from time to time by selling stockholders. The document matters to investors because it identifies the maximum number of shares covered and the holders’ ability to resell them under the registration statement.

Key Highlights

  • The prospectus supplement was filed on September 10, 2026.
  • OS Therapies’ S-3 registration statement was previously filed on August 8, 2025, and became effective on August 25, 2025.
  • Olshan Frome Wolosky LLP provided the legal opinion.

OS Therapies Inc (AMEX: OSTX) filed a prospectus supplement covering resale of up to 5,874,094 common shares by selling stockholders.

S-3 Supplement Covers Common Shares

The supplement was filed on September 10, 2026. That registration statement carries file number 333-289443. OS Therapies also included an opinion from Olshan Frome Wolosky LLP. The document was signed for the company by President and Chief Executive Officer Paul A. Romness, MPH.

Prospectus Supplement Covers Common Stock

The resale is by selling stockholders, who may resell the shares from time to time.